Anti-high mobility group box-1 monoclonal antibody treatment of brain edema induced by influenza infection and lipopolysaccharide.
Identifieur interne : 000275 ( PubMed/Corpus ); précédent : 000274; suivant : 000276Anti-high mobility group box-1 monoclonal antibody treatment of brain edema induced by influenza infection and lipopolysaccharide.
Auteurs : Nobuyuki Nosaka ; Kazuki Hatayama ; Mutsuko Yamada ; Yousuke Fujii ; Masato Yashiro ; Hidenori Wake ; Hirokazu Tsukahara ; Masahiro Nishibori ; Tsuneo MorishimaSource :
- Journal of medical virology [ 1096-9071 ] ; 2018.
English descriptors
- KwdEn :
- Animals, Antibodies, Monoclonal (administration & dosage), Brain Edema (chemically induced), Brain Edema (pathology), Brain Edema (therapy), Disease Models, Animal, Female, HMGB1 Protein (antagonists & inhibitors), HMGB1 Protein (immunology), Immunologic Factors (administration & dosage), Japan, Lipopolysaccharides (administration & dosage), Lipopolysaccharides (toxicity), Mice, Inbred BALB C, Orthomyxoviridae Infections (complications), Treatment Outcome.
- MESH :
- chemical , administration & dosage : Antibodies, Monoclonal, Immunologic Factors, Lipopolysaccharides.
- chemical , antagonists & inhibitors : HMGB1 Protein.
- chemical , toxicity : Lipopolysaccharides.
- geographic : Japan.
- chemically induced : Brain Edema.
- complications : Orthomyxoviridae Infections.
- chemical , immunology : HMGB1 Protein.
- pathology : Brain Edema.
- therapy : Brain Edema.
- Animals, Disease Models, Animal, Female, Mice, Inbred BALB C, Treatment Outcome.
Abstract
Encephalopathy is a major cause of influenza-associated child death and severe neurological sequelae in Japan, highlighting the urgent need for new therapeutic strategies. In this study, we evaluated the effects of anti-high mobility group box-1 monoclonal antibody (α-HMGB1) treatment on brain edema induced by influenza A virus (IAV) and lipopolysaccharide in 4-week-old BALB/c female mice. The results showed that administration of 7.5 mg/kg α-HMGB1 1 h after IAV (A/Puerto Rico/8/34) inoculation significantly alleviated brain edema at 48 h after IAV inoculation, as confirmed by the suppression of Evans Blue dye leakage and matrix metallopeptidase-9 mRNA expression in the brain. Moreover, we also observed suppression of oxidative stress and different cytokines in IAV-inoculated mice. The expression of plasminogen activator inhibitor-1 was also attenuated following treatment with α-HMGB1. Notably, α-HMGB1 treatment had no effect on virus propagation in the lung. In summary, anti-HMGB1 treatment may improve the prognosis in cases with influenza-associated encephalopathy by attenuating brain edema and reducing the inflammatory responses induced by HMGB1.
DOI: 10.1002/jmv.25076
PubMed: 29573352
Links to Exploration step
pubmed:29573352Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Anti-high mobility group box-1 monoclonal antibody treatment of brain edema induced by influenza infection and lipopolysaccharide.</title><author><name sortKey="Nosaka, Nobuyuki" sort="Nosaka, Nobuyuki" uniqKey="Nosaka N" first="Nobuyuki" last="Nosaka">Nobuyuki Nosaka</name><affiliation><nlm:affiliation>Department of Pediatrics, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.</nlm:affiliation></affiliation></author><author><name sortKey="Hatayama, Kazuki" sort="Hatayama, Kazuki" uniqKey="Hatayama K" first="Kazuki" last="Hatayama">Kazuki Hatayama</name><affiliation><nlm:affiliation>Department of Pediatrics, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.</nlm:affiliation></affiliation></author><author><name sortKey="Yamada, Mutsuko" sort="Yamada, Mutsuko" uniqKey="Yamada M" first="Mutsuko" last="Yamada">Mutsuko Yamada</name><affiliation><nlm:affiliation>Department of Pediatrics, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.</nlm:affiliation></affiliation></author><author><name sortKey="Fujii, Yousuke" sort="Fujii, Yousuke" uniqKey="Fujii Y" first="Yousuke" last="Fujii">Yousuke Fujii</name><affiliation><nlm:affiliation>Department of Pediatrics, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.</nlm:affiliation></affiliation></author><author><name sortKey="Yashiro, Masato" sort="Yashiro, Masato" uniqKey="Yashiro M" first="Masato" last="Yashiro">Masato Yashiro</name><affiliation><nlm:affiliation>Department of Pediatrics, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.</nlm:affiliation></affiliation></author><author><name sortKey="Wake, Hidenori" sort="Wake, Hidenori" uniqKey="Wake H" first="Hidenori" last="Wake">Hidenori Wake</name><affiliation><nlm:affiliation>Department of Pharmacology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.</nlm:affiliation></affiliation></author><author><name sortKey="Tsukahara, Hirokazu" sort="Tsukahara, Hirokazu" uniqKey="Tsukahara H" first="Hirokazu" last="Tsukahara">Hirokazu Tsukahara</name><affiliation><nlm:affiliation>Department of Pediatrics, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.</nlm:affiliation></affiliation></author><author><name sortKey="Nishibori, Masahiro" sort="Nishibori, Masahiro" uniqKey="Nishibori M" first="Masahiro" last="Nishibori">Masahiro Nishibori</name><affiliation><nlm:affiliation>Department of Pharmacology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.</nlm:affiliation></affiliation></author><author><name sortKey="Morishima, Tsuneo" sort="Morishima, Tsuneo" uniqKey="Morishima T" first="Tsuneo" last="Morishima">Tsuneo Morishima</name><affiliation><nlm:affiliation>Department of Pediatrics, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2018">2018</date><idno type="RBID">pubmed:29573352</idno><idno type="pmid">29573352</idno><idno type="doi">10.1002/jmv.25076</idno><idno type="wicri:Area/PubMed/Corpus">000275</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000275</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Anti-high mobility group box-1 monoclonal antibody treatment of brain edema induced by influenza infection and lipopolysaccharide.</title><author><name sortKey="Nosaka, Nobuyuki" sort="Nosaka, Nobuyuki" uniqKey="Nosaka N" first="Nobuyuki" last="Nosaka">Nobuyuki Nosaka</name><affiliation><nlm:affiliation>Department of Pediatrics, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.</nlm:affiliation></affiliation></author><author><name sortKey="Hatayama, Kazuki" sort="Hatayama, Kazuki" uniqKey="Hatayama K" first="Kazuki" last="Hatayama">Kazuki Hatayama</name><affiliation><nlm:affiliation>Department of Pediatrics, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.</nlm:affiliation></affiliation></author><author><name sortKey="Yamada, Mutsuko" sort="Yamada, Mutsuko" uniqKey="Yamada M" first="Mutsuko" last="Yamada">Mutsuko Yamada</name><affiliation><nlm:affiliation>Department of Pediatrics, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.</nlm:affiliation></affiliation></author><author><name sortKey="Fujii, Yousuke" sort="Fujii, Yousuke" uniqKey="Fujii Y" first="Yousuke" last="Fujii">Yousuke Fujii</name><affiliation><nlm:affiliation>Department of Pediatrics, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.</nlm:affiliation></affiliation></author><author><name sortKey="Yashiro, Masato" sort="Yashiro, Masato" uniqKey="Yashiro M" first="Masato" last="Yashiro">Masato Yashiro</name><affiliation><nlm:affiliation>Department of Pediatrics, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.</nlm:affiliation></affiliation></author><author><name sortKey="Wake, Hidenori" sort="Wake, Hidenori" uniqKey="Wake H" first="Hidenori" last="Wake">Hidenori Wake</name><affiliation><nlm:affiliation>Department of Pharmacology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.</nlm:affiliation></affiliation></author><author><name sortKey="Tsukahara, Hirokazu" sort="Tsukahara, Hirokazu" uniqKey="Tsukahara H" first="Hirokazu" last="Tsukahara">Hirokazu Tsukahara</name><affiliation><nlm:affiliation>Department of Pediatrics, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.</nlm:affiliation></affiliation></author><author><name sortKey="Nishibori, Masahiro" sort="Nishibori, Masahiro" uniqKey="Nishibori M" first="Masahiro" last="Nishibori">Masahiro Nishibori</name><affiliation><nlm:affiliation>Department of Pharmacology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.</nlm:affiliation></affiliation></author><author><name sortKey="Morishima, Tsuneo" sort="Morishima, Tsuneo" uniqKey="Morishima T" first="Tsuneo" last="Morishima">Tsuneo Morishima</name><affiliation><nlm:affiliation>Department of Pediatrics, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.</nlm:affiliation></affiliation></author></analytic><series><title level="j">Journal of medical virology</title><idno type="eISSN">1096-9071</idno><imprint><date when="2018" type="published">2018</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Antibodies, Monoclonal (administration & dosage)</term><term>Brain Edema (chemically induced)</term><term>Brain Edema (pathology)</term><term>Brain Edema (therapy)</term><term>Disease Models, Animal</term><term>Female</term><term>HMGB1 Protein (antagonists & inhibitors)</term><term>HMGB1 Protein (immunology)</term><term>Immunologic Factors (administration & dosage)</term><term>Japan</term><term>Lipopolysaccharides (administration & dosage)</term><term>Lipopolysaccharides (toxicity)</term><term>Mice, Inbred BALB C</term><term>Orthomyxoviridae Infections (complications)</term><term>Treatment Outcome</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antibodies, Monoclonal</term><term>Immunologic Factors</term><term>Lipopolysaccharides</term></keywords><keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>HMGB1 Protein</term></keywords><keywords scheme="MESH" type="chemical" qualifier="toxicity" xml:lang="en"><term>Lipopolysaccharides</term></keywords><keywords scheme="MESH" type="geographic" xml:lang="en"><term>Japan</term></keywords><keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Brain Edema</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Orthomyxoviridae Infections</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>HMGB1 Protein</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Brain Edema</term></keywords><keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Brain Edema</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Disease Models, Animal</term><term>Female</term><term>Mice, Inbred BALB C</term><term>Treatment Outcome</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Encephalopathy is a major cause of influenza-associated child death and severe neurological sequelae in Japan, highlighting the urgent need for new therapeutic strategies. In this study, we evaluated the effects of anti-high mobility group box-1 monoclonal antibody (α-HMGB1) treatment on brain edema induced by influenza A virus (IAV) and lipopolysaccharide in 4-week-old BALB/c female mice. The results showed that administration of 7.5 mg/kg α-HMGB1 1 h after IAV (A/Puerto Rico/8/34) inoculation significantly alleviated brain edema at 48 h after IAV inoculation, as confirmed by the suppression of Evans Blue dye leakage and matrix metallopeptidase-9 mRNA expression in the brain. Moreover, we also observed suppression of oxidative stress and different cytokines in IAV-inoculated mice. The expression of plasminogen activator inhibitor-1 was also attenuated following treatment with α-HMGB1. Notably, α-HMGB1 treatment had no effect on virus propagation in the lung. In summary, anti-HMGB1 treatment may improve the prognosis in cases with influenza-associated encephalopathy by attenuating brain edema and reducing the inflammatory responses induced by HMGB1.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">29573352</PMID><DateCompleted><Year>2019</Year><Month>06</Month><Day>03</Day></DateCompleted><DateRevised><Year>2019</Year><Month>06</Month><Day>03</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1096-9071</ISSN><JournalIssue CitedMedium="Internet"><Volume>90</Volume><Issue>7</Issue><PubDate><Year>2018</Year><Month>07</Month></PubDate></JournalIssue><Title>Journal of medical virology</Title><ISOAbbreviation>J. Med. Virol.</ISOAbbreviation></Journal><ArticleTitle>Anti-high mobility group box-1 monoclonal antibody treatment of brain edema induced by influenza infection and lipopolysaccharide.</ArticleTitle><Pagination><MedlinePgn>1192-1198</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/jmv.25076</ELocationID><Abstract><AbstractText>Encephalopathy is a major cause of influenza-associated child death and severe neurological sequelae in Japan, highlighting the urgent need for new therapeutic strategies. In this study, we evaluated the effects of anti-high mobility group box-1 monoclonal antibody (α-HMGB1) treatment on brain edema induced by influenza A virus (IAV) and lipopolysaccharide in 4-week-old BALB/c female mice. The results showed that administration of 7.5 mg/kg α-HMGB1 1 h after IAV (A/Puerto Rico/8/34) inoculation significantly alleviated brain edema at 48 h after IAV inoculation, as confirmed by the suppression of Evans Blue dye leakage and matrix metallopeptidase-9 mRNA expression in the brain. Moreover, we also observed suppression of oxidative stress and different cytokines in IAV-inoculated mice. The expression of plasminogen activator inhibitor-1 was also attenuated following treatment with α-HMGB1. Notably, α-HMGB1 treatment had no effect on virus propagation in the lung. In summary, anti-HMGB1 treatment may improve the prognosis in cases with influenza-associated encephalopathy by attenuating brain edema and reducing the inflammatory responses induced by HMGB1.</AbstractText><CopyrightInformation>© 2018 Wiley Periodicals, Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Nosaka</LastName><ForeName>Nobuyuki</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0002-7722-0701</Identifier><AffiliationInfo><Affiliation>Department of Pediatrics, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hatayama</LastName><ForeName>Kazuki</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yamada</LastName><ForeName>Mutsuko</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fujii</LastName><ForeName>Yousuke</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yashiro</LastName><ForeName>Masato</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wake</LastName><ForeName>Hidenori</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Pharmacology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tsukahara</LastName><ForeName>Hirokazu</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nishibori</LastName><ForeName>Masahiro</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Pharmacology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morishima</LastName><ForeName>Tsuneo</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Aichi Medical University, Aichi, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2018</Year><Month>03</Month><Day>31</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Med Virol</MedlineTA><NlmUniqueID>7705876</NlmUniqueID><ISSNLinking>0146-6615</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D024243">HMGB1 Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C582808">HMGB1 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007155">Immunologic Factors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008070">Lipopolysaccharides</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000911" MajorTopicYN="N">Antibodies, Monoclonal</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001929" MajorTopicYN="N">Brain Edema</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D024243" MajorTopicYN="N">HMGB1 Protein</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="Y">antagonists & inhibitors</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007155" MajorTopicYN="N">Immunologic Factors</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007564" MajorTopicYN="N" Type="Geographic">Japan</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008070" MajorTopicYN="N">Lipopolysaccharides</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000633" MajorTopicYN="Y">toxicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009976" MajorTopicYN="N">Orthomyxoviridae Infections</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">brain edema</Keyword><Keyword MajorTopicYN="Y">encephalopathy</Keyword><Keyword MajorTopicYN="Y">high mobility group box-1</Keyword><Keyword MajorTopicYN="Y">influenza virus</Keyword><Keyword MajorTopicYN="Y">monoclonal antibody</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>10</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>03</Month><Day>06</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>3</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>6</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>3</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29573352</ArticleId><ArticleId IdType="doi">10.1002/jmv.25076</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/StressCovidV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000275 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000275 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= StressCovidV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:29573352
|texte= Anti-high mobility group box-1 monoclonal antibody treatment of brain edema induced by influenza infection and lipopolysaccharide.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:29573352" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a StressCovidV1
| This area was generated with Dilib version V0.6.33. |  |